Printer Friendly

MEDICIS ANNOUNCES APPROVAL OF ADDITIONAL STRENGTHS OF SOLODYN.

Medicis (NYSE:MRX), Scottsdale, Ariz. has announced that the U.S. Food and DrugAdministration (FDA) has approved additional strengths of SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. The company believes all forms of SOLODYN currently approved for use, including the 55 mg, 80 mg and 105 mg dosages, are covered by its patent rights, which include several issued patents and two patent applications for which the U.S. Patent and Trademark Office (USPTO) recently issued Notices of Allowance.

"We are very pleased to announce the approval of these additional strengths of SOLODYN, the most prescribed branded dermatology product in the United States1 and leading dermatology product by dollars worldwide,2" said Jonah Shacknai, Chairman and Chief Executive Officer of Medicis. "These three new strengths will complement the current SOLODYN lineup to offer physicians greater weight-based dosing precision of SOLODYN, and make SOLODYN the first and only extended release minocycline with eight FDA-approved dosing strengths. We believe physicians and patients will appreciate the value of this greater dosing precision."

According to the American Academy of Dermatology, acne is the most common skin disorder in the U.S., affecting 40 million to 50 million Americans.3 In 2009, there were over 4 million patient visits to dermatologists for acne.4 Greater than 5.6 million prescriptions were written by dermatologists for minocycline, doxycycline and/or tetracycline, totaling over $1.2 billion in branded and generic retail dollars. Approximately 35% of the 5.6 million prescriptions were written for branded products.5

About SOLODYN Extended Release Tablets

Launched to dermatologists in July 2006 after approval by FDA on May 8, 2006, SOLODYN is the only branded oral minocycline approved for once daily dosage in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. SOLODYN was the first approved minocycline in extended release tablet form. Minocycline is lipid soluble, and distributes in the skin and sebum.

The dosing and administration for SOLODYN is based on extensive, multi-year clinical trials conducted by Medicis in which over 1,000 patients participated. The recommended dosage for SOLODYN is 1 mg/kg daily. In Medicis-sponsored studies, higher doses of SOLODYN (2- and 3-mg/kg/day) were tested against 1 mg/kg/day SOLODYN and did not show additional therapeutic benefits in the treatment of inflammatory lesions of acne. Higher doses have not been shown to be of additional benefit, and may be associated with more acute vestibular side effects.6

SOLODYN has three issued patents. U.S. Patent No. 5,908,838, which expires in 2018, relates to the use of the SOLODYN unique dissolution rate. U.S. Patent No. 7,541,347, which expires in 2027, relates to the use of the 90 mg controlled-release oral dosage form of minocycline to treat acne. U.S. Patent No. 7,544,373, which expires in 2027, relates to the composition of the 90 mg dosage form. In addition, the USPTO issued Notices of Allowance for the company's U.S. Application No. 11/166,817 on April 2, 2010, and for its U.S. Application No. 12/253,845 on July 20, 2010. The company also has a number of additional U.S. patent applications associated with the SOLODYN program on file at the USPTO, several of which contemplated these additional dosage forms.

With the addition of the strengths announced in this press release, SOLODYN is now available by prescription in the eight following extended release tablet dosages:

-- 45 mg (NDC #99207-460-10 and NDC #99207-460-30); -- 55 mg (NDC #99207-465-30); -- 65 mg (NDC #99207-463-30); -- 80 mg (NDC #99207-466-30); -- 90 mg (NDC #99207-461-10 and NDC #99207-461-30); -- 105 mg (NDC #99207-467-30); -- 115 mg (NDC #99207-464-30); and -- 135 mg (NDC #99207-462-10 and NDC #99207-462-30).

When used as directed, SOLODYN is well tolerated and effective for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. The most commonly reported side effects associated with the use of SOLODYN were headache, fatigue, dizziness and pruritus. Minocycline, like other tetracyclines, can cause fetal harm when administered to a pregnant woman. Tetracycline drugs should not be used during tooth development (last half of pregnancy and up to 8 years of age) as they may cause permanent discoloration of teeth. Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range from mild to life-threatening; therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Central nervous system side effects including light-headedness, dizziness or vertigo have been reported with minocycline therapy, but were not significant in SOLODYN clinical investigations. In rare cases, photosensitivity has been reported. SOLODYN should not be used during pregnancy nor by individuals of either gender who are attempting to conceive a child while on therapy; concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. SOLODYN is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. Safety beyond 12 weeks of use has not been established. Full prescribing information for SOLODYN can be obtained by contacting Medicis. For more information about SOLODYN, including full prescribing information, visit www.Solodyn.com.

The company expects product supply to be available for shipping to wholesalers within the quarter, and anticipates promotion and sample distribution of SOLODYN to physicians shortly after initial shipment.

SOLODYN currently is manufactured by WellSpring Pharmaceutical Canada Corp. in Oakville, Ontario, Canada, and AAIPharma Inc. in Wilmington, North Carolina.

About Medicis

Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. The company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic and aesthetic categories. The company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.

The company's products include the brands DYSPORT(R) (abobotulinumtoxinA) 300 Units for Injection, PERLANE(R) Injectable Gel, PERLANE-L(TM) Injectable Gel with 0.3% Lidocaine, RESTYLANE(R) Injectable Gel, RESTYLANE-L(TM) Injectable Gel with 0.3% Lidocaine, DYNACIN(R) (minocycline HCl Tablets, USP), LOPROX(R) (ciclopirox) Gel 0.77% and Shampoo 1%, PLEXION(R) (sodium sulfacetamide 10% and sulfur 5%) Cleanser, Cleansing Cloths and SCT, SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets, TRIAZ(R) (benzoyl peroxide) 3%, 6% and 9% Cleansers, Pads and Foaming Cloths, VANOS(R) (fluocinonide) Cream 0.1%, ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, AMMONUL(R) (sodium phenylacetate and sodium benzoate) Injection 10%/10%, BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder, the LIPOSONIX(TM) system7 and the over-the-counter brand ESOTERICA(R).

For more information about Medicis, please visit the company's website at www.Medicis.com. Printed copies of the company's complete audited financial statements are available free of charge upon request.

NOTE: Full prescribing information for any Medicis prescription product is available by contacting the company. All trademarks are the property of their respective owners.

1 IMS Health. National Prescription Audit (NPA). Data through June 2010. Data on file, Medicis Pharmaceutical Corporation.

2 IMS Health. Knowledge Link -- Version: 5.0. Data through March 2010. Data on file, Medicis Pharmaceutical Corporation.

3 American Academy of Dermatology. "Acne Facts." http://www.aad.org/media/background/factsheets/fact_acne.html. Accessed August 18, 2010.

4 IMS Health. Quarterly NDTI database. December 2009. Data on file, Medicis Pharmaceutical Corporation.

5 IMS Health. NPA. Data through June 2010. Data on file, Medicis Pharmaceutical Corporation.

6 MP-0104-01, "A Randomized, Double-Blind, Placebo-Controlled Phase II Dose Ranging Study of an Oral Extended Release Formulation of Minocycline as Primary Therapy for Acne Vulgaris in Participants 12-30 Years of Age."

7 The LIPOSONIX(TM) system is not approved or cleared for sale in the U.S.

CONTACT: Medicis Media Kara Stancell Investors Sean Andrews (480) 291-5854
COPYRIGHT 2010 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Date:Sep 29, 2010
Words:1345
Previous Article:DERMACYTE APPEARS TO IMPROVE FINE LINES ON SKIN.
Next Article:LUMINEX LAUNCHES NEW CYSTIC FIBROSIS TEST.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters